微信小陈
微信小章| 产品名称： | Loucy |
|---|---|
| 商品货号： | TS211610 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | T lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | T-cell acute lymphoblastic leukemia |
| Age： | 38 years |
| Gender： | female |
| Ethnicity： | White |
| Applications： | This cell line may be of value in evaluating the role of t(16;20) in the etiology of T-ALL. It is important for genetic studies. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Karyotype： | 45,X,5q-,t(16;20)(p12;q13)
Ref  Ben-Bassat H, et al. Establishment of a human T-acute lymphoblastic leukemia cell line with a (16;20) chromosome translocation. Cancer Genet. Cytogenet. 49: 241-248, 1990. PubMed: 2208060 |
| Derivation： | The Loucy cell line was established in 1987 from the peripheral blood of a patient with T-cell acute lymphoblastic leukemia (T-ALL) obtained two months prior to her death |
| Clinical Data： | 38 years adult
female
White |
| Antigen Expression： | OKT3+, OKT4+, THB4+, J5 +/-, OKT6-, TdT-, and HLA-DR- |
| Oncogene： | p53 + overexpressed; (mutated, GTG --> ATG mutation at codon 272)
RefProkocimer M, et al. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (loucy) with t(16:20) and 5q- chromosomal aberrations. Leuk. Lymphoma 29: 607-611, 1998. PubMed: 9643574 |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 3 to 5 x 105 viable cells/mL. Interval: Maintain cultures at cell concentrations between 3 x 105 and 3 x 106 viable cells/mL. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 11,13 D16S539: 11 D5S818: 12 D7S820: 9,10 THO1: 8,9.3 TPOX: 8,9 vWA: 16,17 |
| Population Doubling Time： | 24 to 36 hrs |
| Name of Depositor： | H Ben-Bassat |
| Deposited As： | human |
| Year of Origin： | November, 1987 |
| References： | Ben-Bassat H, et al. Establishment of a human T-acute lymphoblastic leukemia cell line with a (16;20) chromosome translocation. Cancer Genet. Cytogenet. 49: 241-248, 1990. PubMed: 2208060 Prokocimer M, et al. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (loucy) with t(16:20) and 5q- chromosomal aberrations. Leuk. Lymphoma 29: 607-611, 1998. PubMed: 9643574 Ben-Bassat H, et al. Establishment of a human T-acute lymphoblastic leukemia cell line with a (16;20) chromosome translocation. Cancer Genet. Cytogenet. 49: 241-248, 1990. PubMed: 2208060 Prokocimer M, et al. P53 gene mutation in a T-acute lymphoblastic leukemia cell line (loucy) with t(16:20) and 5q- chromosomal aberrations. Leuk. Lymphoma 29: 607-611, 1998. PubMed: 9643574 |